There has been a swing towards in vivo CAR-T therapies lately, as big pharmas sign acquisition deals and new therapies hit ...

Discover the emerging class of degrader-antibody conjugates – a modality that is drawing increasing interest from biotech ...

Researchers have used modified CRISPR to silence the extra chromosome 21 in Down syndrome cells, showing promising ...

Single-cell analysis is reshaping drug discovery, but interpretation remains slow. AI single cell approaches may close the ...

AACR 2026 saw thousands gathered in San Diego, California, where major progress in cancer research was revealed.

Delve into the field of PARP inhibitors, a class that has gained traction in ovarian, breast, and prostate cancers.

Discover some of the new atopic dermatitis treatments in clinical development that could overcome existing challenges in the ...

Gilead Sciences is entering a pivotal moment in its evolution. Long defined by its dominance in antivirals, particularly for HIV, the company now faces a strategic challenge: the need to meaningfully ...

Discover eight allergy companies leading the way in 2026, developing allergy therapies that go beyond emergency management.

VCs and universities struggle with different goals and timelines, but tech transfer is helping turn academic science into ...

Delve into the pipeline strategy of major biotech Amgen, which is increasingly diversifying its growth engines.